Loading...
Loading...
NeoStem, Inc.
("NeoStem" or the "Company"), a leader in the emerging cellular therapy
market, today announced the licensing of three families of patents from the
University of California, San Francisco ("UCSF"). NeoStem's worldwide
exclusive license to these patents provides incremental protection for the
Company's human Regulatory T cell ("Treg") platform, and complements the
recently announced collaboration with UCSF and the laboratories of Drs.
Jeffrey Bluestone and Qizhi Tang, to develop Tregs for the treatment of type 1
diabetes, steroid resistant asthma, and organ transplant rejection.
The three patent families cover methods to isolate, expand and use Tregs with
therapeutic potential for autoimmune disorders, including U.S. patent
7,722,862, which claims a cellular immunotherapy for the treatment of type 1
diabetes.
"In the U.S., type 1 diabetes affects 1.3 million people and has an economic
cost of over $14 billion, numbers which are significantly higher worldwide,"
said Dr. Douglas W. Losordo, Chief Medical Officer of NeoStem. "These patents
bolster our existing portfolio in the Treg arena and enhance our ability to
combat autoimmune diseases such as type 1 diabetes using Treg therapy."
NeoStem's patent estate for its Treg program now includes exclusive rights to
22 issued patents in U.S. and major international commercial geographies and
covers isolation, activation, expansion and methods of treating or preventing
certain conditions and/or diseases using Tregs.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in